Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia.

IF 6.5 2区医学 Q1 IMMUNOLOGY

Oncoimmunology Pub Date : 2023-11-03 eCollection Date: 2023-01-01 DOI:10.1080/2162402X.2023.2276490

Iria Fernandez Botana, Giulia Pagano, Etienne Moussay, Jerome Paggetti

引用次数: 0

Abstract

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. It is characterized by a high dependency on interactions with the surrounding immune landscape, highlighting its suitability for immune-mediated therapeutic interventions. We recently revealed that the cytokine IL-27 exerts a strong anti-tumor role in CLL through a T-cell-mediated mechanism.

Abstract Image

查看原文本刊更多论文

白细胞介素27治疗慢性淋巴细胞白血病的免疫抑制。

慢性淋巴细胞白血病（CLL）是西方世界最常见的成人白血病。其特点是高度依赖于与周围免疫环境的相互作用，突出了其对免疫介导的治疗干预的适用性。我们最近发现，细胞因子IL-27通过T细胞介导的机制在CLL中发挥强大的抗肿瘤作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGYIMMUNOLOGY-IMMUNOLOGY

CiteScore

12.50

自引率

2.80%

发文量

276

审稿时长

24 weeks

期刊介绍： OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy. As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology. The journal covers a wide range of topics, including: -Basic and translational studies in immunology of both solid and hematological malignancies -Inflammation, innate and acquired immune responses against cancer -Mechanisms of cancer immunoediting and immune evasion -Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells -Immunological effects of conventional anticancer therapies.